Events & Presentations
Glucotrack April 2026 Investor Presentation
Title
Download
Press Releases
GlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common Stock
Rutherford, NJ, April 13, 2023 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, today announced the pricing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10…
GlucoTrack Announces Proposed Underwritten Public Offering of Common Stock
Rutherford, NJ, April 12, 2023 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, today announced that it intends to offer shares of common stock in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this…
GLUCOTRACK PROVIDES SHAREHOLDER UPDATE
Rutherford, NJ, March 14, 2023 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter. To Our Valued Shareholders, At the outset, we would like…
GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK
INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM Rutherford, NJ, Oct. 14, 2022 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today that Mark Tapsak, PhD, has joined the Company as Vice President of Sensor Technology, effective immediately….
GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor
Rutherford, NJ and Or Yehuda, Israel, June 22, 2022 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has provided an update on the development of GlucoTrack 2.0 (or “Gen 2”). In…
GlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol Change
To begin trading under the Nasdaq Symbol GCTK Rutherford, NJ and Or Yehuda, Israel, March 14, 2022 — GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), formerly known as Integrity Applications, Inc., (Nasdaq: IGAP), innovator of GlucoTrack®, a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and…